Hedgehog訊號通路抑制劑市場－全球產業規模、佔有率、趨勢、機會、預測：學名藥、劑量、終端用戶、地區及競爭格局，2021-2031年

全球 Hedgehog 通路抑制劑市場預計將從 2025 年的 5.6912 億美元成長到 2031 年的 8.6275 億美元，複合年成長率為 7.18%。

這些定向小分子藥物透過抑制Hedgehog訊號路徑中的Smoothed蛋白，從而抑制細胞不受控制的增殖，主要用於不適合手術或放射治療的進行性基底細胞癌和急性骨髓性白血病患者。市場成長的主要驅動力是這些癌症在全球範圍內日益普遍，以及當局部治療效果不佳時，對能夠提供全身性疾病控制的口服標靶治療的需求不斷成長。然而，這些藥物的高毒性是其面臨的主要挑戰，諸如肌肉痙攣和脫髮症等副作用常常導致治療中斷和患者依從性差。此疾病的負擔極為沉重，據估計，到2025年，美國將新增22,010例急性骨髓性白血病病例，因此，儘管存在安全性和抗藥性問題，但迫切需要創新治療方法。

市場促進因素

刺蝟訊號通路抑制劑市場的主要促進因素是全球基底細胞癌和急性骨髓性白血病發病率的上升，這歸因於人口老化和紫外線照射增加等因素。據估計，到2025年，美國將有11,090人死於急性骨髓性白血病，每年新增基底細胞癌病例360萬例。這種日益加重的疾病負擔推動了對有效全身療法的臨床需求，尤其是在手術不可行的情況下。同時，精準醫療的日益普及以及由此帶來的便捷口服化療藥物需求的成長，也顯著影響著市場動態。患者和醫護人員都傾向於選擇能夠控制全身性疾病的治療方法，從而減少因靜脈化療而需要住院治療的次數。大型製藥企業的強勁表現進一步支撐了這一趨勢。例如，太陽製藥工業公司報告稱，其 2025 會計年度第三季度全球特種產品銷售額為 3.7 億美元，部分原因是刺猬抑製劑（如 Odomzo）的強勁表現，這表明靶向口服療法如何提高收入並保持高市場需求。

市場挑戰

刺蝟訊號通路抑制劑持續市場擴張的主要障礙在於其顯著的毒性。諸如嚴重肌肉痙攣、脫髮症和味覺障礙等不利事件常常迫使患者中斷或完全停止治療。這種依從性不足直接阻礙了產生收入，因為患者往往無法堅持控制全身性疾病所需的長期治療方法。因此，這些藥物的實際市場滲透率與其適應症的高發生率並不匹配，因為副作用常常會削弱耐受性有限的患者的治療效益。考慮到目標患者群體極為龐大，這些安全問題的影響尤其顯著。預計到2025年，美國將新增約540萬例基底細胞癌和鱗狀細胞癌病例。儘管理論需求巨大，但藥物不耐受的臨床現實導致高脫落率，從而減少了可計費治療週期的總數，顯著限制了市場成長。

市場趨勢

市場上，人們對新型藥物再利用製劑，尤其是局部用藥，越來越感興趣，希望以此減輕口服 Hedgehog 路徑抑制劑的全身毒性。這項策略轉變旨在透過局部治療作用並最大限度地減少全身不利事件（例如肌肉痙攣，這些不良反應通常是導致治療中斷的原因），從而提高患者的依從性。一個值得注意的例子是局部用藥帕替吉布，它被開發用於治療基底細胞癌，同時降低全身暴露。近期臨床進展表明，這種對提高耐受性的關注至關重要。例如，2025 年 8 月，Sol-Gel Technologies 公司宣布其用於預防Gorlin症候群的局部用藥帕替吉布凝膠「SGT-610」的大型 III 期臨床試驗已完成患者招募。同時，臨床研究正積極拓展其適應症，從基底細胞癌擴展到包括急性骨髓性白血病(AML) 等骨髓惡性腫瘤。研究人員正利用真實世界臨床數據來證實這些抑制劑聯合治療對無法耐受強化療患者的療效，顯著擴大了其適應症範圍。積極的臨床結果進一步支持了這一擴展。例如，一項於2025年4月發表的真實世界臨床研究顯示，50名接受玻璃-德吉布抑制劑（glass-de-Gibb）一線治療的急性髓系白血病（AML）患者中，50.0%達到了完全緩解或類似的療效。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球Hedgehog訊號通路抑制劑市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 學名藥（Glass-de-Gib、Sonide-de-Gib、Bismode-de-Gib）
  • 劑型（膠囊、注射）
  • 依最終使用者（居家醫療、醫院、專科診所）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美Hedgehog訊號通路抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲Hedgehog訊號通路抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區Hedgehog通路抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東與非洲刺蝟訊號通路抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美刺蝟訊號通路抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球 Hedgehog 通路抑制劑市場：SWOT 分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• BridgeBio Pharma, Inc.
• Eli Lilly and Company
• F. Hoffmann La Roche Ltd.
• Impact Therapeutics Inc.
• Kintor Pharmaceutical Limited
• Max Biopharma Inc.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Sanofi SA

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Hedgehog Pathway Inhibitors Market is projected to expand from USD 569.12 Million in 2025 to USD 862.75 Million by 2031, demonstrating a 7.18% CAGR. These targeted small molecule pharmaceuticals work by inhibiting the Smoothened protein in the Hedgehog signaling pathway to arrest uncontrolled cell growth, primarily indicated for advanced basal cell carcinoma and acute myeloid leukemia in patients unsuitable for surgery or radiation. The market's growth is largely fueled by the increasing global prevalence of these cancers and a rising demand for oral targeted therapies that provide systemic disease control where local treatments are insufficient. A key challenge, however, is the high toxicity profile of these agents, with side effects like muscle spasms and alopecia frequently leading to treatment discontinuation or noncompliance. The significant disease burden, exemplified by an estimated 22,010 new acute myeloid leukemia cases in the U.S. in 2025, underscores the critical need for therapeutic innovation despite safety and resistance issues.

Market Driver

The primary driver for the Hedgehog Pathway Inhibitors Market is the rising global incidence of basal cell carcinoma and acute myeloid leukemia, driven by factors such as aging populations and increased UV exposure. This escalating disease burden, highlighted by an estimated 11,090 acute myeloid leukemia deaths and 3.6 million annual basal cell carcinoma diagnoses in the U.S. in 2025, intensifies the clinical demand for effective systemic therapies, particularly for cases where surgery is not feasible. Concurrently, the increasing embrace of precision medicine and the growing preference for convenient oral chemotherapeutic options are significantly influencing market dynamics. Both patients and practitioners favor treatments that offer systemic disease control with oral administration, thereby reducing the need for hospital visits associated with intravenous chemotherapy. This trend is further evidenced by the strong commercial performance of major pharmaceutical companies, such as Sun Pharmaceutical Industries, which reported Global Specialty sales of USD 370 million in Q3 FY25, partly attributed to the robust performance of Hedgehog inhibitors like Odomzo, illustrating how targeted oral therapies are boosting revenue and sustaining high market demand.

Market Challenge

A significant impediment to sustained market expansion for Hedgehog Pathway Inhibitors is their pronounced toxicity profile. Adverse events, including severe muscle spasms, alopecia, and dysgeusia, frequently compel patients to interrupt or completely discontinue treatment. This noncompliance directly hinders revenue generation, as patients often cannot adhere to the necessary prolonged therapeutic regimens for systemic disease control. Consequently, the actual market penetration of these drugs lags behind the high prevalence of their indications, as side effects often diminish therapeutic benefits for patients with limited tolerance. The impact of these safety concerns is particularly evident when considering the substantial target patient population, with approximately 5.4 million basal and squamous cell skin cancer diagnoses projected in the U.S. in 2025. Despite this vast theoretical demand, the clinical reality of drug intolerance results in high dropout rates, thereby significantly constraining market growth by reducing the total volume of billable therapeutic cycles.

Market Trends

The market is increasingly focusing on novel repurposed drug formulations, especially topical agents, to counteract the systemic toxicity of oral Hedgehog pathway inhibitors. This strategic shift aims to enhance patient adherence by localizing therapeutic effects and minimizing systemic adverse events such as muscle spasms that often lead to treatment discontinuation. A notable example is topical patidegib, developed to treat basal cell carcinoma with reduced systemic exposure. This emphasis on improved tolerability is demonstrated by recent clinical advancements, including Sol-Gel Technologies' announcement in August 2025 regarding the completion of enrollment for its pivotal Phase 3 trial of SGT-610, a topical patidegib gel, intended as a preventive therapy for Gorlin syndrome. Concurrently, clinical research is actively broadening the indications beyond basal cell carcinoma to encompass hematological malignancies like acute myeloid leukemia (AML). Researchers are leveraging real-world evidence to confirm the efficacy of these inhibitors in combination regimens for patients unable to tolerate intensive chemotherapy, significantly expanding their therapeutic application. This diversification is further supported by positive outcomes in clinical practice, such as a real-world study published in April 2025 showing that 50.0% of 50 AML patients treated with first-line glasdegib therapy achieved complete remission or a comparable response.

Key Market Players

• BridgeBio Pharma, Inc.
• Eli Lilly and Company
• F. Hoffmann La Roche Ltd.
• Impact Therapeutics Inc.
• Kintor Pharmaceutical Limited
• Max Biopharma Inc.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Sanofi S.A

Report Scope

In this report, the Global Hedgehog Pathway Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hedgehog Pathway Inhibitors Market, By Generic Drug

• Glasdegib
• Sonidegib
• Vismodegib

Hedgehog Pathway Inhibitors Market, By Dosage

• Capsule
• Injection

Hedgehog Pathway Inhibitors Market, By End User

• Homecare
• Hospitals
• Specialty Clinics

Hedgehog Pathway Inhibitors Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hedgehog Pathway Inhibitors Market.

Available Customizations:

Global Hedgehog Pathway Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hedgehog Pathway Inhibitors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Generic Drug (Glasdegib, Sonidegib, Vismodegib)
  • 5.2.2. By Dosage (Capsule, Injection)
  • 5.2.3. By End User (Homecare, Hospitals, Specialty Clinics)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Hedgehog Pathway Inhibitors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Generic Drug
  • 6.2.2. By Dosage
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hedgehog Pathway Inhibitors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Generic Drug
      • 6.3.1.2.2. By Dosage
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Hedgehog Pathway Inhibitors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Generic Drug
      • 6.3.2.2.2. By Dosage
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Hedgehog Pathway Inhibitors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Generic Drug
      • 6.3.3.2.2. By Dosage
      • 6.3.3.2.3. By End User

7. Europe Hedgehog Pathway Inhibitors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Generic Drug
  • 7.2.2. By Dosage
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Hedgehog Pathway Inhibitors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Generic Drug
      • 7.3.1.2.2. By Dosage
      • 7.3.1.2.3. By End User
  • 7.3.2. France Hedgehog Pathway Inhibitors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Generic Drug
      • 7.3.2.2.2. By Dosage
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Hedgehog Pathway Inhibitors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Generic Drug
      • 7.3.3.2.2. By Dosage
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Hedgehog Pathway Inhibitors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Generic Drug
      • 7.3.4.2.2. By Dosage
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Hedgehog Pathway Inhibitors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Generic Drug
      • 7.3.5.2.2. By Dosage
      • 7.3.5.2.3. By End User

8. Asia Pacific Hedgehog Pathway Inhibitors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Generic Drug
  • 8.2.2. By Dosage
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Hedgehog Pathway Inhibitors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Generic Drug
      • 8.3.1.2.2. By Dosage
      • 8.3.1.2.3. By End User
  • 8.3.2. India Hedgehog Pathway Inhibitors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Generic Drug
      • 8.3.2.2.2. By Dosage
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Hedgehog Pathway Inhibitors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Generic Drug
      • 8.3.3.2.2. By Dosage
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Hedgehog Pathway Inhibitors Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Generic Drug
      • 8.3.4.2.2. By Dosage
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Hedgehog Pathway Inhibitors Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Generic Drug
      • 8.3.5.2.2. By Dosage
      • 8.3.5.2.3. By End User

9. Middle East & Africa Hedgehog Pathway Inhibitors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Generic Drug
  • 9.2.2. By Dosage
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Hedgehog Pathway Inhibitors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Generic Drug
      • 9.3.1.2.2. By Dosage
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Hedgehog Pathway Inhibitors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Generic Drug
      • 9.3.2.2.2. By Dosage
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Hedgehog Pathway Inhibitors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Generic Drug
      • 9.3.3.2.2. By Dosage
      • 9.3.3.2.3. By End User

10. South America Hedgehog Pathway Inhibitors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Generic Drug
  • 10.2.2. By Dosage
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Hedgehog Pathway Inhibitors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Generic Drug
      • 10.3.1.2.2. By Dosage
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Hedgehog Pathway Inhibitors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Generic Drug
      • 10.3.2.2.2. By Dosage
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Hedgehog Pathway Inhibitors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Generic Drug
      • 10.3.3.2.2. By Dosage
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Hedgehog Pathway Inhibitors Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. BridgeBio Pharma, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Eli Lilly and Company
• 15.3. F. Hoffmann La Roche Ltd.
• 15.4. Impact Therapeutics Inc.
• 15.5. Kintor Pharmaceutical Limited
• 15.6. Max Biopharma Inc.
• 15.7. Merck KGaA
• 15.8. Novartis AG
• 15.9. Pfizer Inc.
• 15.10. Sanofi S.A

16. Strategic Recommendations

17. About Us & Disclaimer